Campbell & CO Investment Adviser LLC Cuts Position in Amphastar Pharmaceuticals, Inc. $AMPH

Campbell & CO Investment Adviser LLC lessened its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 3.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 45,789 shares of the company’s stock after selling 1,777 shares during the quarter. Campbell & CO Investment Adviser LLC owned approximately 0.10% of Amphastar Pharmaceuticals worth $1,327,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Systematic Financial Management LP increased its stake in Amphastar Pharmaceuticals by 32.6% during the first quarter. Systematic Financial Management LP now owns 326,546 shares of the company’s stock worth $9,467,000 after purchasing an additional 80,198 shares during the period. Hotchkis & Wiley Capital Management LLC increased its stake in Amphastar Pharmaceuticals by 13.7% during the first quarter. Hotchkis & Wiley Capital Management LLC now owns 270,150 shares of the company’s stock worth $7,832,000 after purchasing an additional 32,630 shares during the period. AlphaQuest LLC increased its stake in Amphastar Pharmaceuticals by 138.4% during the 1st quarter. AlphaQuest LLC now owns 11,593 shares of the company’s stock worth $336,000 after buying an additional 6,731 shares during the period. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Amphastar Pharmaceuticals during the 1st quarter worth approximately $39,000. Finally, Fuller & Thaler Asset Management Inc. increased its stake in Amphastar Pharmaceuticals by 11.5% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,263,598 shares of the company’s stock worth $36,632,000 after buying an additional 130,672 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on AMPH. Wells Fargo & Company cut their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, May 8th. Piper Sandler cut their price objective on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a research report on Friday, August 8th. Needham & Company LLC upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $36.00 price target on the stock in a report on Tuesday, August 12th. Bank of America upped their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. restated a “neutral” rating and set a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Two analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $31.60.

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH opened at $30.34 on Wednesday. The firm has a market capitalization of $1.41 billion, a PE ratio of 11.36 and a beta of 0.76. The business’s fifty day moving average price is $24.28 and its 200 day moving average price is $25.78. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.29 and a quick ratio of 2.21. Amphastar Pharmaceuticals, Inc. has a 12 month low of $20.39 and a 12 month high of $53.96.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.